For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, CRISPR Therapeutics AG’s stock clocked out at $37.78, down -3.00% from its previous closing price of $38.95. In other words, the price has decreased by -$3.00 from its previous closing price. On the day, 1.65 million shares were traded. CRSP stock price reached its highest trading level at $38.5 during the session, while it also had its lowest trading level at $36.74.
Ratios:
To gain a deeper understanding of CRSP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.07 and its Current Ratio is at 22.07. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on February 14, 2025, Upgraded its rating to Outperform and sets its target price to $99 from $60 previously.
On February 12, 2025, TD Cowen Upgraded its rating to Hold which previously was Sell but kept the price unchanged to $35.
On February 03, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $65.H.C. Wainwright initiated its Buy rating on February 03, 2025, with a $65 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 21 ’25 when Kulkarni Samarth sold 10,031 shares for $41.23 per share. The transaction valued at 413,578 led to the insider holds 195,085 shares of the business.
Bruno Julianne sold 1,714 shares of CRSP for $70,668 on Mar 21 ’25. The Chief Operating Officer now owns 10,544 shares after completing the transaction at $41.23 per share. On Mar 21 ’25, another insider, Prasad Raju, who serves as the Chief Financial Officer of the company, sold 2,197 shares for $41.23 each. As a result, the insider received 90,582 and left with 16,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 3240560384 and an Enterprise Value of 1560426624. For the stock, the TTM Price-to-Sale (P/S) ratio is 87.27 while its Price-to-Book (P/B) ratio in mrq is 1.68. Its current Enterprise Value per Revenue stands at 41.819 whereas that against EBITDA is -3.488.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.81, which has changed by -0.3272792 over the last 52 weeks, in comparison to a change of 0.05279863 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $67.88, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is -8.15%, while the 200-Day Moving Average is calculated to be -18.16%.
Shares Statistics:
It appears that CRSP traded 2.32M shares on average per day over the past three months and 2960510 shares per day over the past ten days. A total of 85.74M shares are outstanding, with a floating share count of 82.46M. Insiders hold about 4.33% of the company’s shares, while institutions hold 69.04% stake in the company. Shares short for CRSP as of 1743379200 were 20510014 with a Short Ratio of 8.85, compared to 1740700800 on 20808121. Therefore, it implies a Short% of Shares Outstanding of 20510014 and a Short% of Float of 27.08.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
